Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced the filing of a provisional patent application in the United States for INM-405 and other unique compositions as cannabinoid-based topical therapies.
